KEYTRUDA® (pembrolizumab) in the adjuvant treatment of Stage III melanoma

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection.

PDF, 4.52 MB

A slide deck on KEYTRUDA in the adjuvant treatment of patients with Stage III melanoma containing information on the associated risks for such patients and how KEYTRUDA can support them, through a clinical data presentation of KEYNOTE-054.

Please refer to the Summary of Product Characteristics for more information on adverse events associated with KEYTRUDA.

More information about KEYTRUDA® (pembrolizumab) in melanoma:

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.